Venetoclax plus gilteritinib is effective in preclinical models of <i>FLT3</i> -mutant BCL11B-a lineage-ambiguous leukemiaLindsey E. Montefiori, Charles G. Mullighan, Pradyumna Baviskar et al.|Blood|2025Cited by 7
Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumorAndrew M. Fleming, Andrew J. Murphy, Carolyn M. Jablonowski et al.|Cell Reports|2026Cited by 1
Abstract 6057: The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiationRuth W. Wang'ondu, Charles G. Mullighan, Devanand Bondage et al.|Cancer Research|2026Cited by 0